What is the name of the modified human tPA that binds to fibrin and converts plasminogen to plasmin?

The modified human tissue plasminogen activator (tPA) that binds to fibrin and converts plasminogen to plasmin is known as Tenecteplase. This agent is specifically designed to have a longer half-life and enhanced fibrin specificity compared to other thrombolytic agents. By binding to fibrin, Tenecteplase effectively localizes its activity to the clot, promoting the conversion of plasminogen to plasmin mainly at the site of a thrombus, which is crucial for effective clot resolution.

In comparison, Alteplase is a recombinant form of tPA but does not have the same modified properties that Tenecteplase possesses. Urokinase is another thrombolytic agent but works differently and does not specifically target fibrin as Tenecteplase does. Reteplase, while also a modified tPA, has a different mechanism and doesn't have the same binding affinity to fibrin as Tenecteplase. Each of these alternatives has distinct pharmacological characteristics, but Tenecteplase's unique binding to fibrin is what sets it apart in this context.